The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients
The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients
复制标题
DOI：
10.3851/imp3196
复制
发表时间：
2018-01-01
影响因子：
1.2
通讯作者：
Chayama, Kazuaki
中科院分区：
文献类型：
--
作者：
Kurihara, Mio;Tsuge, Masataka;Chayama, Kazuaki
背景资料：尽管核苷/核苷酸类似物治疗被认为通过调节炎性细胞因子/趋化因子来抑制慢性B型肝炎（CH B），但其机制仍不清楚。在这项研究中，血清细胞因子/趋化因子水平测定恩替卡韦治疗的慢性乙型肝炎患者，并与抗病毒反应进行了分析。方法：共有78例日本慢性乙型肝炎患者参加，血清细胞因子/趋化因子水平测定在基线和在12，24和48周恩替卡韦治疗使用MULTIPLEX试剂盒。恩替卡韦治疗的抗病毒应答与B型肝炎表面抗原（HBsAg）滴度和血清干扰素-γ-诱导蛋白10（IP-10）水平显著相关（12 w; P=0.0002; OR=0.020 [95%CI 0.002，0.156]，P=0.003; OR=0.042 [95%CI 0.005，0.336]）。血清巨噬细胞源性趋化因子（MDC）水平较低（= 1323.13 pg/ml）的HBeAg阳性患者比HBeAg仍阳性患者更早出现HBeAg丢失（P=0.044）。恩替卡韦治疗降低HBsAg与较高的初始肿瘤坏死因子-α显著相关（TNF-α）水平（>= 15.20 pg/ml）和较高的丙氨酸氨基转移酶水平（>= 73 IU/l; P=0.009; OR=18.460 [95% CI 2.044，166.709]，P=0.022; OR=7.709 [95% CI 1.341，44.327]）。本研究的结果表明，恩替卡韦治疗后细胞因子/趋化因子水平的变化与CHB患者抗病毒治疗的反应有关。监测血清细胞因子/趋化因子水平可能有助于预测HBV DNA和HBsAg和HBe血清转换的减少。
Background: Although nucleoside/nucleotide analogue therapy is thought to suppress chronic hepatitis B (CHB) via regulation of inflammatory cytokines/chemokines, the mechanism is still unclear. In this study, serum cytokine/chemokine levels were measured in CHB patients treated with entecavir, and the association with antiviral response was analysed.Methods: A total of 78 Japanese patients with CHB were enrolled, and serum cytokine/chemokine levels were measured at baseline and at 12, 24 and 48 weeks of entecavir treatment using the MULTIPLEX kit.Results: Antiviral response to entecavir treatment was significantly associated with hepatitis B surface antigen (HBsAg) titre and serum interferon-gamma-inducible protein 10 (IP-10) level (12w; P=0.0002; OR=0.020 [95% CI 0.002, 0.156], P=0.003; OR=0.042 [95% CI 0.005, 0.336], respectively). HBe-positive patients whose serum macrophage-derived chemokine (MDC) level was lower (= 1,323.13 pg/ml) achieved hepatitis B e antigen (HBeAg) loss earlier than those who remained HBeAg-positive (P=0.044). HBsAg reduction by entecavir treatment was significantly associated with higher initial tumour necrosis factor-alpha (TNF-alpha) level (>= 15.20 pg/ml) and higher alanine aminotransferase level (>= 73 IU/l; P=0.009; OR=18.460 [95% CI 2.044, 166.709], P=0.022; OR=7.709 [95% CI 1.341, 44.327], respectively).Conclusions: Results of the present study indicate that changes in cytokine/chemokine levels following entecavir therapy are associated with response to antiviral therapy in CHB patients. Monitoring of serum cytokine/chemokine levels could be useful for predicting reduction of HBV DNA and HBsAg and HBe seroconversion.